Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

The introduction of inhibitors of cholesterol biosynthesis offers a new approach to treatment of hypercholesterolemia. One such agent, lovastatin (formerly, mevinolin), causes significant reductions in plasma cholesterol levels. This action can be enhanced by bile acid sequestrants. In this study, lovastatin and colestipol hydrochloride together were administered to ten patients with primary moderate hypercholesterolemia. Compared with a control period, the combined-drug therapy caused a 36% reduction in plasma total cholesterol level, a 48% decrease in low-density lipoprotein (LDL) cholesterol level, and a 17% increase in high-density lipoprotein cholesterol level. The reduction in LDL cholesterol level was due to three factors: (1) a 27% decrease in the production rate of LDL, (2) a 20% increase in fractional catabolic rate of LDL, and (3) a 15% depletion of cholesterol in LDL particles. This major reduction in LDL cholesterol level produced by combined-drug therapy may be valuable for prevention of coronary heart disease in high-risk patients with primary moderate hypercholesterolemia.

Original languageEnglish (US)
Pages (from-to)33-38
Number of pages6
JournalJournal of the American Medical Association
Volume257
Issue number1
StatePublished - 1987

Fingerprint

Colestipol
Lovastatin
Hypercholesterolemia
LDL Cholesterol
LDL Lipoproteins
Cholesterol
Anticholesteremic Agents
Drug Therapy
Lipoprotein(a)
Therapeutics
Bile Acids and Salts
HDL Cholesterol
Coronary Disease

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{ffd0f0e9cd534ea7a86fcd004f17f0d7,
title = "Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol",
abstract = "The introduction of inhibitors of cholesterol biosynthesis offers a new approach to treatment of hypercholesterolemia. One such agent, lovastatin (formerly, mevinolin), causes significant reductions in plasma cholesterol levels. This action can be enhanced by bile acid sequestrants. In this study, lovastatin and colestipol hydrochloride together were administered to ten patients with primary moderate hypercholesterolemia. Compared with a control period, the combined-drug therapy caused a 36{\%} reduction in plasma total cholesterol level, a 48{\%} decrease in low-density lipoprotein (LDL) cholesterol level, and a 17{\%} increase in high-density lipoprotein cholesterol level. The reduction in LDL cholesterol level was due to three factors: (1) a 27{\%} decrease in the production rate of LDL, (2) a 20{\%} increase in fractional catabolic rate of LDL, and (3) a 15{\%} depletion of cholesterol in LDL particles. This major reduction in LDL cholesterol level produced by combined-drug therapy may be valuable for prevention of coronary heart disease in high-risk patients with primary moderate hypercholesterolemia.",
author = "Vega, {Gloria L} and Grundy, {Scott M}",
year = "1987",
language = "English (US)",
volume = "257",
pages = "33--38",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol

AU - Vega, Gloria L

AU - Grundy, Scott M

PY - 1987

Y1 - 1987

N2 - The introduction of inhibitors of cholesterol biosynthesis offers a new approach to treatment of hypercholesterolemia. One such agent, lovastatin (formerly, mevinolin), causes significant reductions in plasma cholesterol levels. This action can be enhanced by bile acid sequestrants. In this study, lovastatin and colestipol hydrochloride together were administered to ten patients with primary moderate hypercholesterolemia. Compared with a control period, the combined-drug therapy caused a 36% reduction in plasma total cholesterol level, a 48% decrease in low-density lipoprotein (LDL) cholesterol level, and a 17% increase in high-density lipoprotein cholesterol level. The reduction in LDL cholesterol level was due to three factors: (1) a 27% decrease in the production rate of LDL, (2) a 20% increase in fractional catabolic rate of LDL, and (3) a 15% depletion of cholesterol in LDL particles. This major reduction in LDL cholesterol level produced by combined-drug therapy may be valuable for prevention of coronary heart disease in high-risk patients with primary moderate hypercholesterolemia.

AB - The introduction of inhibitors of cholesterol biosynthesis offers a new approach to treatment of hypercholesterolemia. One such agent, lovastatin (formerly, mevinolin), causes significant reductions in plasma cholesterol levels. This action can be enhanced by bile acid sequestrants. In this study, lovastatin and colestipol hydrochloride together were administered to ten patients with primary moderate hypercholesterolemia. Compared with a control period, the combined-drug therapy caused a 36% reduction in plasma total cholesterol level, a 48% decrease in low-density lipoprotein (LDL) cholesterol level, and a 17% increase in high-density lipoprotein cholesterol level. The reduction in LDL cholesterol level was due to three factors: (1) a 27% decrease in the production rate of LDL, (2) a 20% increase in fractional catabolic rate of LDL, and (3) a 15% depletion of cholesterol in LDL particles. This major reduction in LDL cholesterol level produced by combined-drug therapy may be valuable for prevention of coronary heart disease in high-risk patients with primary moderate hypercholesterolemia.

UR - http://www.scopus.com/inward/record.url?scp=0023232731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023232731&partnerID=8YFLogxK

M3 - Article

C2 - 3537351

AN - SCOPUS:0023232731

VL - 257

SP - 33

EP - 38

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 1

ER -